SF

All is good - just getting impatient like everyone else.

Looking thru my rose colored glasses - 

I agree - a deal is in the air and right now HEPA has the strong hand - deservedly so - they have the most skin in the game.  They undoubtedly have a high level of confidence in the trial endpoints being met.  The ROFR on the US territory implies another suitor. A HEPA takeout of RVX coupled with a Nasdaq listing of HL-US could be a viable option as floated on the IV board and provide retail shareholders with a nice reward . 

Does HEPA have the pipeline to promote and market a pioneer standard of care epigenetic CV concept in the US? - it would seem to me that a known existing player AZN, PFE, GSK, SNY, NVS would be better suited to roll out epigenetic therapies.  

JMO,

Chicagoest